Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-CHINA: AZD0780 in dyslipidemia with inadequately controlled LDL-C
CTR20243982Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of laroprovstat in dyslipidemia, hypercholesterolemia, sponsored by AstraZeneca. Started Jan 2025; status: active.
02
Drugs
laroprovstat
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on CTR20243982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243982.